Novo Thirteen IV 2500, by Novo Nordisk Pharma, contains Catridecacog (genetical recombination), a recombinant coagulation factor XIII A-subunit used for long-term prophylactic treatment of bleeding in patients with congenital factor XIII A-subunit deficiency. It is supplied as 2,500 IU 1 bottle with dissolving solution (YJ code: 6343443D1027).
Novo Thirteen IV 2500
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).